UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3997-4013

2013

Volltextzugriff (PDF)

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

Archives of pathology & laboratory medicine (1976), 2014-02, Vol.138 (2), p.241-256

2014

Volltextzugriff (PDF)

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study

BMC cancer, 2018-12, Vol.18 (1), p.1266-1266, Article 1266

2018

Volltextzugriff (PDF)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines

Breast cancer : basic and clinical research, 2010-01, Vol.4, p.35-41

2010

Volltextzugriff (PDF)

Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation

Diagnostic pathology, 2024-01, Vol.19 (1), p.10-10, Article 10

2024

Volltextzugriff (PDF)

Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry

Modern pathology, 2013, Vol.26 (1), p.1-9

2013

Volltextzugriff (PDF)

Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines

Archives of pathology & laboratory medicine (1976), 2009-04, Vol.133 (4), p.611-612

2009

Volltextzugriff (PDF)

Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)

Journal of bone and mineral research, 2012-01, Vol.27 (1), p.79-92

2012

Volltextzugriff (PDF)

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

Modern pathology, 2022-08, Vol.35 (8), p.1075-1082

2022

Volltextzugriff (PDF)

HER2-Low Breast Cancers: New Opportunities and Challenges

American journal of clinical pathology, 2022-03, Vol.157 (3), p.328-336

2022

Volltextzugriff (PDF)

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX ® Testing

Cancers, 2023-01, Vol.15 (3), p.903

2023

Volltextzugriff (PDF)

GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor

Human pathology, 2012-11, Vol.43 (11), p.2033-2040

2012

Volltextzugriff (PDF)

P53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer

Human pathology, 2017-10, Vol.68, p.22-25

2017

Volltextzugriff (PDF)

Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer

Journal of clinical oncology, 2006-07, Vol.24 (19), p.3039-3047

2006

Volltextzugriff (PDF)

HER2-Low Breast Cancers

American journal of clinical pathology, 2022-03, Vol.157 (3), p.328-336

2022

Volltextzugriff (PDF)

The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor–Negative Breast Cancer and a More Aggressive Clinical Course

Clinical cancer research, 2005-01, Vol.11 (1), p.186-192

2005

Volltextzugriff (PDF)

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Journal of clinical oncology, 2015-08, Vol.33 (24), p.2695-2704

2015

Volltextzugriff (PDF)

Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26

Cancer medicine (Malden, MA), 2019-08, Vol.8 (9), p.4176-4188

2019

Volltextzugriff (PDF)

HER2-low breast cancers: Current insights and future directions

Seminars in diagnostic pathology, 2022-09, Vol.39 (5), p.305-312

2022

Volltextzugriff (PDF)

Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort

American journal of clinical pathology, 2023-05, Vol.159 (5), p.484-491

2023

Volltextzugriff (PDF)

Standardization of Tissue Handling From the OR to the Laboratory

AORN journal, 2014-06, Vol.99 (6), p.810-813

Hicks, David G.

2014

Volltextzugriff (PDF)

Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine

Biotechnic & histochemistry, 2024-09, p.1-13

2024

Volltextzugriff (PDF)

Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression

Archives of pathology & laboratory medicine (1976), 2024-02, Vol.148 (2), p.242-255

2024

Volltextzugriff (PDF)

In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry

Laboratory investigation, 2024-03, Vol.104 (3), p.100309-100309, Article 100309

2024

Volltextzugriff (PDF)

The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations

Cancers, 2023-01, Vol.15 (3), p.808

2023

Volltextzugriff (PDF)

1 – 25 von 957

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(865)
Mit Volltextzugriff
(758)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines

Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation

Delay to formalin fixation ‘cold ischemia time’: effect on ERBB2 detection by in-situ hybridization and immunohistochemistry

Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines

Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP)

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles

HER2-Low Breast Cancers: New Opportunities and Challenges

The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX ® Testing

GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor

P53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer

Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast Cancer

HER2-Low Breast Cancers

The Expression of Fascin, an Actin-Bundling Motility Protein, Correlates with Hormone Receptor–Negative Breast Cancer and a More Aggressive Clinical Course

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26

HER2-low breast cancers: Current insights and future directions

Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort

Standardization of Tissue Handling From the OR to the Laboratory

Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine

Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression

In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry

The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations

Suchergebnisse filtern